ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for blood cancer patients in japan?
Disease control OngoingThis study is testing a new drug called Golcadomide (BMS-986369) in about 85 people in Japan whose T-cell lymphoma has come back or not responded to treatment. The goal is to check the drug's safety and how well it works against the cancer. Participants will receive the drug and …
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo shows promise against tough lymphoma
Disease control OngoingThis phase 2 trial tests a new combination treatment for a rare type of lymphoma (CD30-positive peripheral T-cell lymphoma). It combines a targeted drug (brentuximab vedotin) with standard chemotherapy. The goal is to see if this approach improves the number of patients who achie…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC